))
DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications. Use cases for the DrugPatentWatch platform include: - Branded pharmaceutical global business intelligence and forecasting - Generic drug and API manufacturer portfolio management - Wholesalers preventing overstock of off-patent drugs - Healthcare payer formulary management and budget management
…
continue reading
A paper presented at the 2nd International Conference on Systems Medicine, AI, and Drug Repurposing proposes a novel approach to overcoming the financial barriers associated with repurposing generic drugs through…Source저자 DrugPatentWatch
…
continue reading
A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) costs for biologic drugs in the United States. The research,…Source저자 DrugPatentWatch
…
continue reading
A recent article in Communications of the ACM explores opportunities for “Permissionless innovation” in pharmaceuticals. “Permissionless innovation” refers to the freedom to explore new technologies or businesses without needing prior…Source저자 DrugPatentWatch
…
continue reading
LACTOSE-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Lactose-Free Medicines from Amazon This guide is designed to provide information for healthcare providers to…Source저자 DrugPatentWatch
…
continue reading
GELATIN-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Gelatin-Free Medicines on Amazon This guide is designed to provide information for healthcare providers to…Source저자 DrugPatentWatch
…
continue reading
Switching pharmaceutical excipients, the inactive components used in drug formulations, can have significant implications for both production costs and market appeal. These components, while not contributing directly to the therapeutic…Source저자 DrugPatentWatch
…
continue reading
Elevate your excipient business strategies with the comprehensive Drug Excipient Business Development Reports from DrugPatentWatch. Designed for excipient manufacturers seeking lucrative opportunities in the pharmaceutical industry, these reports offer invaluable…Source저자 DrugPatentWatch
…
continue reading
The recent paper published in PLOS ONE presents a novel approach for efficiently retrieving a substantial number of patents related to specific technologies. The authors enhance an automated patent landscaping…Source저자 DrugPatentWatch
…
continue reading
A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper patents in the FDA’s Orange Book by pharmaceutical manufacturers. The…Source저자 DrugPatentWatch
…
continue reading
A recent article published in the Journal of Cheminformatics addresses the challenge of confirming the patent status of newly developed compounds, particularly in the pharmaceutical industry, where generating novel structures…Source저자 DrugPatentWatch
…
continue reading
A recent story by NPR echoes the findings of a collaboration between DrugPatentWatch and Bloomberg, which examined increasing competition between generic drug makers. The NPR article discusses the challenges in…Source저자 DrugPatentWatch
…
continue reading
The article “Settled: Patent characteristics and litigation outcomes in the pharmaceutical industry,” explores the relationship between Paragraph IV litigation characteristics and the probability of a Paragraph IV settlement in the…Source저자 DrugPatentWatch
…
continue reading
In the ever-evolving landscape of the biotech and pharmaceutical sectors, accurate valuation of post-revenue drug assets stands as the linchpin for informed and strategic decision-making. The significance of this valuation…Source저자 DrugPatentWatch
…
continue reading
Researchers from West Virginia University College of Law have conducted a study examining the frequency of drug patent invalidations based on inequitable conduct. The findings, published in JAMA, shed light…Source저자 DrugPatentWatch
…
continue reading
In a recent article in Pharmaceutical Executive, Alan Kalton, Senior Vice President of Commercial Strategy at Aktana, sheds light on the critical challenges facing pharmaceutical companies as they confront impending…Source저자 DrugPatentWatch
…
continue reading
1
Maximizing Intellectual Property Value in the Biomedical Sector: A Case Study on Rucaparib Patents
A paper titled “Analysis of Strategy for Extending Patent Protection of Rucaparib” by Zhifeng Wang. discusses the strategies employed by pharmaceutical companies to extend the patent protection period of the…Source저자 DrugPatentWatch
…
continue reading
1
Advancements in In Silico ADMET Modeling: A 20-Year Journey of Machine Learning in Drug Discovery at Bayer Pharma
Over the past two decades, Bayer Pharma has developed an in silico absorption, distribution, metabolism, and excretion (ADMET) platform with the aim of generating models for various pharmacokinetic and physicochemical…Source저자 DrugPatentWatch
…
continue reading
DrugPatentWatch has published a list of research papers citing DrugPatentWatch at https://www.drugpatentwatch.com/citations/ DrugPatentWatch.com is your key to unlocking the world of pharmaceutical research. These primary literature citations can benefit researchers,…Source저자 DrugPatentWatch
…
continue reading
In a systematic review titled “Influencers of Generic Drug Utilization,” researchers aimed to shed light on the key factors influencing the use of generic prescription drugs in the United States.…Source저자 DrugPatentWatch
…
continue reading
The article titled “Reviving an R&D Pipeline: A Step Change in the Phase II Success Rate” discusses Pfizer’s efforts to improve its research and development (R&D) productivity. The pharmaceutical industry…Source저자 DrugPatentWatch
…
continue reading
The FDA conducted a study to identify factors that may predict the likelihood of generic drug marketing applications. The study focused on abbreviated new drug applications (ANDAs) submitted to the…Source저자 DrugPatentWatch
…
continue reading
“Measuring Patent Value Indicators with Patent Renewal Information” aims to address the research gap by constructing a dynamic model that incorporates both ex ante and ex post patent value indicators.…Source저자 DrugPatentWatch
…
continue reading
The article “Maximizing the Value of Drug Patents Before Losing Exclusivity” discusses strategies for biomedical companies to maximize the value of their drug patents before the exclusivity period expires. In…Source저자 DrugPatentWatch
…
continue reading
In a recent STAT article Sanofi CEO Paul Hudson discusses the potential of artificial intelligence (AI) in the pharmaceutical industry. While some in the industry have been hesitant to embrace…Source저자 DrugPatentWatch
…
continue reading
In the world of patents, the right to exclude others from using or selling an invention is granted only during the patent’s validity. Once a patent expires, this exclusivity vanishes.…Source저자 DrugPatentWatch
…
continue reading
Pharmacists play a crucial role in drug repurposing due to the vast amount of opportunities that exist in this innovative approach. Drug development and registration can be costly, time-consuming, and…Source저자 DrugPatentWatch
…
continue reading
In a guest column Kevin Wall, principal consultant and owner of Cincero Consulting, emphasizes the critical importance of selecting the right Contract Development and Manufacturing Organization (CDMO) for drug product…Source저자 DrugPatentWatch
…
continue reading
Loss of exclusivity (LOE) doesn’t have to spell doom for branded drug revenue streams. In the face of impending patent expirations, pharmaceutical companies can adopt key approaches to preserve meaningful…Source저자 DrugPatentWatch
…
continue reading
A recent paper in Expert Opinion on Biological Therapy studies failed fillings for biosimilar drugs. Over the past three decades, biotherapeutics have revolutionized healthcare by providing effective treatments for complex diseases…Source저자 DrugPatentWatch
…
continue reading
DrugPatentWatch now offers single drug reports for purchase on Amazon. These reports provide valuable insights and information about specific drugs. This convenient availability on Amazon allows users to easily access…Source저자 DrugPatentWatch
…
continue reading
A recent paper published in the journal “Intelligent Medicine” article discusses various aspects of using AI and machine learning in the pharmaceutical industry for drug discovery and development. Results The…Source저자 DrugPatentWatch
…
continue reading
A recent study explores the landscape of authorized generics in the United States pharmaceutical market. Authorized generics are brand-name drugs that are marketed without their original branding. The article sheds…Source저자 DrugPatentWatch
…
continue reading
A recent update from Foley & Lardner attorney Courtenay C. Brinckerhoff discusses trends in Inter Partes Review (IPR) and Post Grant Review (PGR) proceedings involving Orange Book and biologic patents, based…Source저자 DrugPatentWatch
…
continue reading
In a recent Insight article published by Global Competition Review, legal experts from Lowenstein Sandler LLP delve into the status of reverse payment cases against pharmaceutical companies. Reverse payment cases…Source저자 DrugPatentWatch
…
continue reading
In the world of prescription drugs, brand-name manufacturers have employed various strategies to maintain revenue streams in the face of generic competition. One such strategy is the use of “authorized…Source저자 DrugPatentWatch
…
continue reading
1
Review of 505(b)(2) Drug Products Approved by USFDA from 2010 to 2020: A Focus on Intellectual Property and Regulatory Considerations
A review article in the Journal of Pharmaceutical Sciences analyzes the trends in drug repurposing through the 505(b)(2) pathway, as approved by the USFDA from 2010 to 2020. The study…Source저자 DrugPatentWatch
…
continue reading
Here’s a summary of a new article that used DrugPatentWatch data: NIH Funding for Patents That Contribute to Market Exclusivity of Drugs Approved 2010–2019 and the Public Interest Protections of…Source저자 DrugPatentWatch
…
continue reading
In a recent article published by IAM Magazine, titled “Why Pharma Companies Should File Patents Later In The R&D Process,” Alexander R. Trimble, PhD, a prominent patent attorney, explores the…Source저자 DrugPatentWatch
…
continue reading
DrugChatter recently launched as an experimental AI chat-based business intelligence tool. Here’s some of the more interesting questions it’s been asked: Cost savings for bulk lipitor Who Invented Advil? What…Source저자 DrugPatentWatch
…
continue reading
Introducing DrugChatter.com: Empowering Access to Biopharmaceutical Drug Insights through AI Chat We are pleased to introduce DrugChatter.com, a groundbreaking platform that redefines the way professionals obtain concise, cited information on…Source저자 DrugPatentWatch
…
continue reading
On NPR’s All Things Considered, Sydney Lupkin asked DrugPatentWatch if drug patents could be used to identify injector pens which could then be swapped to fix drug shortages. Referring to…Source저자 DrugPatentWatch
…
continue reading
1
Utilizing 505(b)(2) Regulatory Pathway for New Drug Applications: An Overview on the Advanced Formulation Approach and Challenges
This article was originally published by Jiayi Chen, Zhifeng Zhao, Xinyu Wang and Jingjun Huang in Drug Repurposing – Advances, Scopes and Opportunities in Drug Discovery and is republished here…Source저자 DrugPatentWatch
…
continue reading
This is a guest post by Oleksandr Topachevskyi at Digital Health Outcomes. Oleksandr may be contacted at sales@digitalho.com Commercial, nonprofit, and government companies are quite good at calculating the costs…Source저자 DrugPatentWatch
…
continue reading
This article was originally published by Guy Shtar, Louise Azulay, Omer Nizri, Lior Rokach & Bracha Shapira in Scientific Data volume 9, Article number: 263 under a Creative Commons Attribution…Source저자 DrugPatentWatch
…
continue reading
DrugPatentWatch has been named to Genetic Engineering News‘ Best of the Web list. The review by Genetic Engineering News profile highlighted the “new training modules designed to help you find…Source저자 DrugPatentWatch
…
continue reading
This is a guest post by Ray Miller and Megan E. Bowers, Ph.D. at DLA Piper. Ray may be contacted at raymond.miller@dlapiper.com. When it comes to protecting therapeutic assets, I…Source저자 DrugPatentWatch
…
continue reading
FEATURED ARTICLE Branded Generics Promise Profits for Drugmakers, Peace of Mind for Patients Developing nations offer welcoming and growing markets as Abbott focuses exclusively on reformulating and marketing off-patent medications…Source저자 DrugPatentWatch
…
continue reading
Drugs contain ingredients with therapeutic activity, so-called “active ingredients” as well as inactive ingredients. These inactive ingredients, called excipients, are included in oral products for various reasons, such as to…Source저자 DrugPatentWatch
…
continue reading
DrugPatentWatch developed this course to help users better understand the complexities and common strategies around brand erosion and generic entry. The positive responses received made it apparent that the course…Source저자 DrugPatentWatch
…
continue reading
DrugPatentWatch has been ranked the “Best Biopharmaceuticals Commercial Business Intelligence Platform” by Global Health & Pharma News This award is dedicated to honoring the innovation, determination and outstanding levels of…Source저자 DrugPatentWatch
…
continue reading
